Why InterMune Inc. Lost Big Today

Shares of InterMune (NASDAQ: ITMN  ) tumbled by more than 15% today, as the company is suffering from a possible trial data leak from a competitor's idiopathic pulmonary fibrosis drug, which successfully passed its phase 3 trials, and put up solid data. David points to one analyst from Summer Street who quickly came to InterMune's defense, saying that while the two drugs are technically competitors, patients would be cycled between them, given the nature of the IPF disease.

In this segment, Motley Fool health-care analyst David Williamson takes a look at ITMN today, a stock he sees as one that could vary wildly up or down by 50% based on what happens with its drug Esbriet. He talks investors through both scenarios, and also discusses what strong trial data vs. weak could mean for the company, and when investors may see results.

Biotech stocks are known for their volatility, but they can also make you rich.
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2819821, ~/Articles/ArticleHandler.aspx, 9/21/2014 6:09:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement